Replimune GroupFRA:7R8 -3.56%32 Market Cap is €810.48 Mil as of Jul. 11, 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,422 Biotechnology companies, Replimune Group ranks better than 78.48% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Replimune Group's share price for the quarter that ended in Mar. 2026 was €6.2. Replimune Group's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 82.72 Mil. Therefore, Replimune Group's market cap for the quarter that ended in Mar. 2026 was €512.85 Mil.
Replimune Group's quarterly market cap
increased
from Sep. 2025 (€280.68 Mil) to Dec. 2025 (€656.96 Mil) but then
declined
from Dec. 2025 (€656.96 Mil) to Mar. 2026 (€512.85 Mil).
Replimune Group's annual market cap
increased
from Mar. 2024 (€460.61 Mil) to Mar. 2025 (€978.98 Mil) but then
declined
from Mar. 2025 (€978.98 Mil) to Mar. 2026 (€512.85 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Replimune Group's Enterprise Value for Today is €672.35 Mil.
Replimune Group (FRA:7R8) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Replimune Group Market Cap Related Terms
Replimune Group Market Cap Historical Data
* Premium members only.
The historical data trend for Replimune Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7R8 vs AVTX, KURA, SANA: Market Cap Comparison
For the Biotechnology subindustry, Replimune Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Replimune Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Replimune Group's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (FRA:7R8) has a Market Cap of €810.48 Mil as of Jul. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #306 out of 1422 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Replimune Group's Market Cap too high?
Replimune Group's current Market Cap is €810.48 Mil. Based on the distribution chart, Replimune Group ranks #306 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Market Cap compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #306 out of 1422 companies for Market Cap. This places Replimune Group in the top 22% of its industry — outperforming the majority of peers. The industry median Market Cap is 120.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.54, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Replimune Group and its competitors. For the Biotechnology industry, the median Market Cap is 120.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Market Cap is €810.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current Market Cap of €810.48 Mil. The current Market Cap is €810.48 Mil. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current Market Cap is €810.48 Mil as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score
Get the complete analysis for FRA:7R8
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7R8 has been successfully added to your 
